Published in Lancet on September 21, 2002
The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev (2008) 5.32
Mechanisms of resistance and susceptibility to experimental visceral leishmaniosis: BALB/c mouse versus Syrian hamster model. Vet Res (2011) 1.00
Visceral leishmaniasis caused by Leishmania infantum in a Spanish patient in Argentina: What is the origin of the infection? Case report. BMC Infect Dis (2004) 0.89
Frequency of MDR1-related p-gp overexpression in Greek Leishmania isolates. Parasitol Res (2014) 0.75
Leishmania in discarded syringes from intravenous drug users. Lancet (2002) 1.95
Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIV/HCV co-infected patients. J Hepatol (2008) 2.14
High prevalence of hepatitis C virus infection among noninjecting drug users: association with sharing the inhalation implements of crack. Liver Int (2008) 2.04
Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology (2009) 1.64
Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS (2006) 1.44
Insulin resistance is associated with liver stiffness in HIV/HCV co-infected patients. Gut (2009) 1.43
[Thirty-six year old male patient with dysphonia refractory to conventional medical treatment]. Enferm Infecc Microbiol Clin (2001) 1.42
The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis (2007) 1.39
Sandflies of the Phlebotomus perniciosus complex: mitochondrial introgression and a new sibling species of P. longicuspis in the Moroccan Rif. Med Vet Entomol (2004) 1.26
Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS (2004) 1.25
Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients. HIV Clin Trials (2003) 1.18
Prevalence of and factors associated with visceral leishmaniasis in human immunodeficiency virus type 1-infected patients in southern Spain. J Clin Microbiol (1998) 1.17
Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther (2008) 1.14
Detection of Leishmania infantum kinetoplast DNA in peripheral blood from asymptomatic individuals at risk for parenterally transmitted infections: relationship between polymerase chain reaction results and other Leishmania infection markers. Am J Trop Med Hyg (2004) 1.12
Transient rebounds of HIV plasma viremia are associated with the emergence of drug resistance mutations in patients on highly active antiretroviral therapy. J Infect (2005) 1.11
Transient rebounds of low-level viraemia among HIV-infected patients under HAART are not associated with virological or immunological failure. Antivir Ther (2002) 1.10
Increased hepatocyte fas expression and apoptosis in HIV and hepatitis C virus coinfection. J Infect Dis (2005) 1.10
Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. J Antimicrob Chemother (2008) 1.05
Use of noninvasive markers to detect Leishmania infection in asymptomatic human immunodeficiency virus-infected patients. J Clin Microbiol (2006) 1.05
Gynaecomastia in HIV-infected men on highly active antiretroviral therapy: association with efavirenz and didanosine treatment. Antivir Ther (2004) 1.04
A common polymorphism in TLR3 confers natural resistance to HIV-1 infection. J Immunol (2011) 1.03
Decrease in serial prevalence of coinfection with hepatitis C virus among HIV-infected patients in Spain, 1997-2006. Clin Infect Dis (2009) 1.03
High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients. Am J Trop Med Hyg (1999) 1.03
Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother (2007) 1.02
CD4+ and CD8+ T lymphocyte regeneration after anti-retroviral therapy in HIV-1-infected children and adult patients. Clin Exp Immunol (2000) 0.99
Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis. Clin Infect Dis (2013) 0.99
Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy. J Clin Microbiol (2002) 0.99
Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load. J Hepatol (2011) 0.98
Frequency of subclinical visceral leishmaniasis in HIV-1-infected patients in Spain. Eur J Clin Microbiol Infect Dis (1996) 0.98
Prevalence and risk factors for abnormal liver stiffness in HIV-infected patients without viral hepatitis coinfection: role of didanosine. Antivir Ther (2010) 0.95
Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response. J Infect (2013) 0.95
Prevalence and factors associated with significant liver fibrosis assessed by transient elastometry in HIV/hepatitis C virus-coinfected patients. J Viral Hepat (2010) 0.95
The high sensitivity of a PCR-ELISA in the diagnosis of cutaneous and visceral leishmaniasis caused by Leishmania infantum. Ann Trop Med Parasitol (2002) 0.94
Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients. J Antimicrob Chemother (2011) 0.93
Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients. AIDS (2012) 0.93
Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis. J Antimicrob Chemother (2008) 0.92
Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients. Antivir Ther (2007) 0.92
Different distributions of hepatitis C virus genotypes among HIV-infected patients with acute and chronic hepatitis C according to interleukin-28B genotype. HIV Med (2011) 0.92
Incidence of and risk factors for insulin resistance in treatment-naive HIV-infected patients 48 weeks after starting highly active antiretroviral therapy. Antivir Ther (2006) 0.92
Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C. Antivir Ther (2006) 0.91
Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis. Clin Infect Dis (2012) 0.90
Risk maps for the presence and absence of Phlebotomus perniciosus in an endemic area of leishmaniasis in southern Spain: implications for the control of the disease. Parasitology (2011) 0.90
Larval anisakids parasitizing the blue whiting, Micromesistius poutassou, from Motril Bay in the Mediterranean region of southern Spain. J Helminthol (2000) 0.90
Liver toxicity of initial antiretroviral drug regimens including two nucleoside analogs plus one non-nucleoside analog or one ritonavir-boosted protease inhibitor in HIV/HCV-coinfected patients. HIV Clin Trials (2012) 0.89
Low sensitivity of peripheral blood smear for diagnosis of subclinical visceral leishmaniasis in human immunodeficiency virus type 1-infected patients. J Clin Microbiol (1998) 0.89
Surface Localization of Buried III-V Semiconductor Nanostructures. Nanoscale Res Lett (2009) 0.89
Liver tolerance of raltegravir-containing antiretroviral therapy in HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother (2011) 0.88
Increasing incidence of hepatocellular carcinoma in HIV-infected patients in Spain. Clin Infect Dis (2012) 0.88
Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients. AIDS (2011) 0.87
Frequency of visceral leishmaniasis relapses in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. Am J Trop Med Hyg (2004) 0.87
Risk of liver decompensation among HIV/hepatitis C virus-coinfected individuals with advanced fibrosis: implications for the timing of therapy. Clin Infect Dis (2013) 0.87
Natural killer KIR3DS1 is closely associated with HCV viral clearance and sustained virological response in HIV/HCV patients. PLoS One (2013) 0.87
Insulin resistance is not associated with liver fibrosis progression in HIV/hepatitis C virus-coinfected patients. J Viral Hepat (2006) 0.86
Chronic hepatitis E in HIV patients: rapid progression to cirrhosis and response to oral ribavirin. Clin Infect Dis (2013) 0.86
Specificity of a commercial indirect immunofluorescence technique in the diagnosis of visceral leishmaniasis in patients infected with HIV-1. Trans R Soc Trop Med Hyg (1996) 0.86
Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: effect of hepatitis virus co-infection and pre-existing fibrosis. J Antimicrob Chemother (2008) 0.86
Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients. J Acquir Immune Defic Syndr (2009) 0.86
HIV-coinfection leads to a modest increase in plasma HCV-RNA load in patients with chronic HCV infection. Antiviral Res (2012) 0.86
Intraspecific variability (rDNA ITS and mtDNA Cyt b) of Phlebotomus sergenti in Spain and Morocco. Acta Trop (2008) 0.86
Reduction of immune system activation in HIV-1-infected patients undergoing highly active antiretroviral therapy. Eur J Clin Microbiol Infect Dis (1999) 0.85
[Erosive gastritis associated with cryptosporidium in 2 patients with AIDS]. Acta Gastroenterol Latinoam (1994) 0.85
Influence of highly active antiretroviral therapy on the outcome of subclinical visceral leishmaniasis in human immunodeficiency virus-infected patients. Clin Infect Dis (2001) 0.85
The changing face of HIV/AIDS in treated patients. Curr HIV Res (2009) 0.85
Evidence of increased risk for leishmania infantum infection among HIV-seronegative intravenous drug users from southern Spain. Eur J Clin Microbiol Infect Dis (2001) 0.84
Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin. J Antimicrob Chemother (2010) 0.84
Activity of (-)alpha-bisabolol against Leishmania infantum promastigotes. Phytomedicine (2009) 0.84
Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection. AIDS (2013) 0.84
Bilateral enophthalmos as a manifestation of HIV infection-related lipoatrophy. HIV Med (2004) 0.84
Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression. Clin Infect Dis (2009) 0.83
Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV–hepatitis C virus-coinfected patients with prior nonresponse or relapse. AIDS (2011) 0.83
Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients. Antivir Ther (2007) 0.83
Interobserver concordance in the assessment of liver fibrosis in HIV/HCV-coinfected patients using transient elastometry. Eur J Gastroenterol Hepatol (2010) 0.83
Incidence of liver damage of uncertain origin in HIV patients not co-infected with HCV/HBV. PLoS One (2013) 0.83
Relationship between osteopenia, free testosterone, and vitamin D metabolite levels in HIV-infected patients with and without highly active antiretroviral therapy. AIDS Res Hum Retroviruses (2005) 0.83
Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance treatment. Eur J Clin Microbiol Infect Dis (2011) 0.82
Liver stiffness measurement versus liver biopsy to predict survival and decompensations of cirrhosis among HIV/hepatitis C virus-coinfected patients. AIDS (2013) 0.82
Application of transient elastometry to differentiate mild from moderate to severe liver fibrosis in HIV/HCV co-infected patients. J Hepatol (2008) 0.82
HAART and the liver: friend or foe? Eur J Med Res (2010) 0.82
LDLr genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN/RBV in HIV/HCV patients. AIDS (2012) 0.82
Liver stiffness correlates with Child-Pugh-Turcotte and MELD scores in HIV/hepatitis C virus-coinfected patients with cirrhosis. Liver Int (2012) 0.82
Pharmacokinetics of fosamprenavir plus ritonavir in human immunodeficiency virus type 1-infected adult subjects with hepatic impairment. Antimicrob Agents Chemother (2009) 0.81
Rhodococcus or mycobacterium? An example of misdiagnosis in HIV infection. AIDS (1997) 0.81
Impact of inosine triphosphatase gene variants on the risk of anemia in HIV/hepatitis C virus-coinfected patients treated for chronic hepatitis C. Clin Infect Dis (2011) 0.81
Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients. Hepatology (2012) 0.81
Incidence of and risk factors for severe hepatotoxicity of nelfinavir-containing regimens among HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother (2006) 0.80
Predicting the risk of an endemic focus of Leishmania tropica becoming established in South-Western Europe through the presence of its main vector, Phlebotomus sergenti Parrot, 1917. Parasitology (2013) 0.80
A review of current anti-HCV treatment regimens and possible future strategies. Expert Opin Pharmacother (2009) 0.80
False-positive results of leishmanin skin test due to phenol-containing diluent. Trans R Soc Trop Med Hyg (2001) 0.80
Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV/hepatitis C virus coinfected patients. AIDS (2008) 0.80
Management of HCV-related end-stage liver disease in HIV-coinfected patients. AIDS Rev (2007) 0.79
Hepatitis C virus genotype 4 in Southern and Central Spain does not originate from recent foreign migration waves. J Med Virol (2013) 0.79